Precision BioSciences Secures $13M From Imugene Convertible Note Maturity As Part of Azer-cel Deal
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences has secured $13 million from the maturity of a convertible note with Imugene, as part of the Azer-cel deal. This includes $9.75 million in cash and $3.25 million in Imugene shares, extending Precision's cash runway into the second half of 2026.
September 03, 2024 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision BioSciences has secured $13 million from Imugene, enhancing its cash position and extending its financial runway into 2026. This financial boost is part of the Azer-cel deal.
The $13 million secured from Imugene, including cash and shares, strengthens Precision BioSciences' financial position, extending its cash runway into 2026. This is a positive development for the company's financial stability and future operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100